On January 6, 2020 AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, reported that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Sr. Vice President, General Counsel, and Interim Chief Financial Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference at 8:00 a.m. PT on Thursday, January 16, 2020 in San Francisco, CA (Press release, AngioDynamics, JAN 6, 2020, View Source [SID1234552742]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation and Q&A breakout session will be accessible through the "Investors" section of the Company’s website at www.angiodynamics.com and will be available for replay following the event.

On January 6, 2020 Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, reported that Bing Wang, Ph.D., Co-Founder and Chief Executive Officer, will present a corporate update on Tuesday, January 14, 2020 at Biotech Showcase being held in San Francisco, from January 13-15, 2020 (Press release, Refuge Biotechnologies, JAN 6, 2020, View Source [SID1234552741]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The corporate presentation will focus on design of intelligent therapeutic cells by leveraging gene engineering technology called CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi). Recent data supporting the company’s lead pipeline candidate, a HER2 CAR-T plus PD-1 knockdown system for various solid tumors, including head and neck, breast and gastrointestinal cancers will be shared.

Details of the presentation are as follows:

Date and Time: Tuesday, January 14, 2020 at 11:15 a.m. PT
Location: Hilton San Francisco Times Square
Track: Franciscan C (Ballroom Level)

On January 6, 2020 BioMarker Strategies, LLC, a company focused on helping make precision medicine more of a reality for patients with solid tumor cancers, reported that President and CEO Jerry Parrott will present at Biotech Showcase on Wednesday, January 15 at 10:15 AM PST (Press release, BioMarker Strategies, JAN 6, 2020, View Source [SID1234552740]). The presentation will take place in Franciscan C, Ballroom Level, Hilton San Francisco Union Square.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Parrott will also participate in the Life Sciences Nation’s RESI at San Francisco conference, which takes place on Tuesday January 14 at the Marines’ Memorial Club & Hotel, and in the BIO One on One Partnering at JPM program, which is organized by the Biotechnology Innovation Industry (BIO), with meeting space available at the San Francisco Marriott Marquis.

These events take place in parallel to the annual J.P. Morgan Healthcare Conference, which is the largest healthcare investment symposium in the industry with more than 9,000 attendees. Other biotechnology, pharmaceutical and life sciences events, including the ones mentioned above, have been also been attracted to San Francisco for what has come to be known to many as JPM Week. For many biotechnology, pharmaceutical and life sciences companies, fund-raising and business development efforts for each year begin with JPM week.

BioMarker Strategies has developed the patented SnapPath Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for solid tumors. SnapPath is the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. The system preserves the molecular integrity of these living cells for ex vivo exposure to immunotherapies and targeted therapies, either alone or in combination. This enables the generation of PathMap Functional Signaling Profiles, which are highly predictive tests for assessing individual solid tumor response to these treatments, because they are based on the dynamic, predictive signaling information available only from live cells.

On January 6, 2020 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, reported that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is scheduled to present on Monday, January 13, 2020, at 4:00 p.m. Pacific Time at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California (Press release, Rocket Pharmaceuticals, JAN 6, 2020, View Source [SID1234552739]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation and Q&A will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.

On January 6, 2019 Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company pioneering the use of DARPin therapeutics to treat serious diseases, reported that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 9:00 AM Pacific Standard Time (12:00 PM Eastern Time; 6:00 PM CET) (Press release, Molecular Partners, JAN 6, 2020, View Source/molecular-partners-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference/" target="_blank" title="View Source/molecular-partners-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference/" rel="nofollow">View Source [SID1234552738]). The presentation, followed by a Q&A session, will be hosted by Dr. Patrick Amstutz, CEO of Molecular Partners.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Audio webcast
The presentation will be webcast live. A copy of the presentation handout as well as a replay of the webcast will be made available on the company’s website View Source under the Investors section. The replay will be available for 30 days following the presentation.

Financial Calendar
February 6, 2020 Publication of Full-year Results 2019 (unaudited)
April 29, 2020 Annual General Meeting
View Source

About the DARPin Difference
DARPin therapeutics are a new class of protein therapeutics opening an extra dimension of multi-specificity and multi-functionality. DARPin candidates can engage more than five targets, offering potential benefits over those offered by conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology is a fast and cost-effective drug discovery engine, producing drug candidates with ideal properties for development and very high production yields.

With their low immunogenicity and long half-life in the bloodstream and the eye, DARPin therapeutics have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. Molecular Partners is partnering with Allergan to advance clinical programs in ophthalmology and is advancing a proprietary pipeline of DARPin drug candidates in oncology and immuno-oncology. The most advanced global product candidate in partnership with Allergan is abicipar, a molecule for which phase 3 data have been filed to the respective regulators in both the US and in Europe. Several DARPin molecules for various ophthalmic indications are also in preclinical development. The most advanced DARPin therapeutic candidate wholly owned by Molecular Partners, MP0250, is in phase 2 clinical development for the treatment of hematological tumors, and has been granted Orphan Drug Designation by the FDA’s Office of Orphan Products Development (OOPD). MP0274, the second-most advanced DARPin candidate owned by Molecular Partners, binds to Her2 and inhibits downstream signaling, which leads to induction of apoptosis. MP0274 is currently in phase 1. The company’s lead immuno-oncology product candidate MP0310 is a FAP x 4-1BB multi-DARPin therapeutic candidate designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator). Molecular Partners has closed a collaboration agreement with Amgen for the exclusive clinical development and commercialization of MP0310. The molecule has entered in phase 1 of clinical development in H2 2019. Molecular Partners is also advancing a growing preclinical and research pipeline in immuno-oncology that features its "I/O toolbox" and additional development programs such as novel therapeutic designs to target peptide-MHC complexes. DARPin is a registered trademark owned by Molecular Partners AG.